Axsome settles Sunosi patent litigation with Hikma; generic entry deferred to 2040

Axsome Therapeutics, Inc.

Settlement with Hikma resolves patent litigation over Sunosi (solriamfetol) generic.
License for Hikma's generic Sunosi begins Sept 1, 2040 (with pediatric exclusivity) or March 1, 2040 (without).
Agreement subject to FTC/DOJ review; other patent litigation against other parties remains pending.
Axsome retains exclusive Sunosi rights until at least 2040, protecting key product revenue.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.